The plant-based antiviral agent, derived from a group of poisonous plants known as 'deadly carrots', appears to be effective against all versions of the disease in the lab.
TG can be effective against a variety of Viruses. The research team confirms that the antiviral isn't being outflanked by the evolving disease. It's interesting to observe the continuous efficacy of TG with the emergence of new variant.
In tests on cell cultures in the lab, it was shown that TG delivered before or during an active infection could block and prevent the SARS-CoV-2 variant.
The researchers wrote in their paper that a single pre-infection dose of TG effectively blocked all single-variant infections and every combination of co-infection at greater than 95 percent relative to controls.
TG seems to break some of the mechanisms that Viruses like SARS-CoV-2 use to replicate themselves and spread throughout the body.
The team writes that all available data shows that TG doesn't prevent viral entry but rather stimulates the production of virus replicating cells.
The Delta variant spread at four times the rate of the Alpha variant and at nine times the rate of theBeta variant, according to the cell culture study.
When co-infections occur, Delta can accelerate the multiplication of other variant. Delta acts as an extra boost for any other variant it's partnering up with if someone succumbs to two versions of the same thing at the same time.
Kin-Chow Chang, a professor of veterinary medicine at the University ofNottingham in the UK, says that the new study has given them better insights into the dominance of the Delta variant.
TG is just as effective against all of them even though we have shown that this variant is the most infectious and promotes production of other variant in co-infections.
There are a lot of people who won't agree to get a jab to protect themselves against the virus, and that's why vaccinations don't reduce the risk completely.
Finding new treatments to manage COVID-19 will remain a high priority for controlling the ongoing global Pandemic. TG is not certain to be as effective against future variants, but the signs are good.
It would take a lot of research to turn TG into something safe for humans, as you might expect from an agent developed from a poisonous plant, and it would take a while to develop treatments from TG.
It's not a guarantee that this antiviral will pass a clinical trial, but it is a huge step in the right direction.
Kin-Chow Chang says that the results point to the potential of TG as a post-exposure prophylactic and an active therapeutic agent.
The research has been published.
